Document is current

Article History

Accepted: 18 August 2024

First Online: 7 September 2024

Declarations

:

: Amy Gye is an employee of Novartis Pharmaceuticals. Stephen Goodall and Richard De Abreu Lourenco have no conflicts to disclose.

: Concept and design: Gye, Goodall, De Abreu Lourenco; acquisition of data: Gye; analysis and interpretation of data: Gye; drafting of the manuscript: Gye, Goodall, De Abreu Lourenco; critical revision of the paper for important intellectual content: Goodall, De Abreu Lourenco; supervision: Goodall, De Abreu Lourenco.

: Individual data used to support this study are not publicly available for ethical and legal reasons. All other sources used in this research are referenced and publicly available.

: Open Access funding enabled and organized by CAUL and its Member Institutions. This research is part of an Industry Doctorate Program at the Centre for Health Economics Research and Evaluation, University of Technology Sydney in collaboration with Novartis Pharmaceuticals Australia. Novartis Pharmaceuticals Australia provided a Research Support Fee.

: The funder had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation of the manuscript. The manuscript was reviewed by Novartis prior to submitting for publication. The views expressed are those of the authors and not necessarily those of Novartis Pharmaceuticals or the Centre for Health Economics Research and Evaluation (CHERE).